Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches

Bronchopulmonary dysplasia (BPD) remains the most prevalent long-term morbidity of surviving extremely preterm infants and is associated with significant health care utilization in infancy and beyond. Recent advances in neonatal care have resulted in improved survival of extremely low birth weight (ELBW) infants; however, the incidence of BPD has not been substantially impacted by novel interventions in this vulnerable population. The multifactorial cause of BPD requires a multi-pronged approach for prevention and treatment. New approaches in assisted ventilation, optimal nutrition, and pharmacologic interventions are currently being evaluated. The focus of this review is the current state of the evidence for pharmacotherapy in BPD. Promising future approaches in need of further study will also be reviewed.

[1]  M. Laughon,et al.  Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study , 2020, BMC Pediatrics.

[2]  D. Tibboel,et al.  Treatment of rat congenital diaphragmatic hernia with sildenafil and NS-304, selexipag's active compound, at the pseudoglandular stage improves lung vasculature. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[3]  J. Pillow,et al.  Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial , 2018, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[4]  J. Martin,et al.  Describing the Increase in Preterm Births in the United States, 2014-2016. , 2018, NCHS data brief.

[5]  R. Lauterbach,et al.  L-citrulline supplementation in the treatment of pulmonary hypertension associated with bronchopulmonary dysplasia in preterm infant: A case report , 2018, SAGE open medical case reports.

[6]  D. Friedman,et al.  Sildenafil and Retinopathy of Prematurity in Preterm Infants with Bronchopulmonary Dysplasia , 2018, The Journal of pediatrics.

[7]  B. Thébaud.  Mesenchymal Stromal Cell Therapy for Respiratory Complications of Extreme Prematurity , 2018, American Journal of Perinatology.

[8]  A. V. van Kaam,et al.  Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study): statistical analysis plan , 2018, Trials.

[9]  C. Meisner,et al.  Long‐Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia , 2018, The New England journal of medicine.

[10]  J. Pillow,et al.  Enteral vitamin A for reducing severity of bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled trial , 2017, BMC Pediatrics.

[11]  A. Papageorghiou,et al.  Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. , 2017, The Lancet. Child & adolescent health.

[12]  N. Finer,et al.  Laryngeal Mask Airway for Surfactant Administration in Neonates: A Randomized, Controlled Trial , 2017, The Journal of pediatrics.

[13]  A. Ohlsson,et al.  Early erythropoiesis-stimulating agents in preterm or low birth weight infants. , 2017, The Cochrane database of systematic reviews.

[14]  L. Doyle,et al.  Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth , 2017, American journal of respiratory and critical care medicine.

[15]  J. A. Pérez,et al.  Effect of Inhaled Nitric Oxide on Survival Without Bronchopulmonary Dysplasia in Preterm Infants: A Randomized Clinical Trial , 2017, JAMA pediatrics.

[16]  L. Doyle,et al.  Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. , 2017, The Cochrane database of systematic reviews.

[17]  S. Kourembanas,et al.  ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury , 2017, Pediatric Research.

[18]  Mohammad Hossein Khosravi,et al.  Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, Lancet.

[19]  A. V. van Kaam,et al.  Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. , 2017, The Cochrane database of systematic reviews.

[20]  Ji Hye Kim,et al.  Two‐Year Follow‐Up Outcomes of Premature Infants Enrolled in the Phase I Trial of Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia , 2017, The Journal of pediatrics.

[21]  D. Mohamed,et al.  Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age , 2017, JAMA.

[22]  L. Palermo,et al.  The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1‐Year Corrected Age , 2017, The Journal of pediatrics.

[23]  P. Davis,et al.  Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants , 2017, The New England journal of medicine.

[24]  Shoo K. Lee,et al.  Revisiting the Definition of Bronchopulmonary Dysplasia: Effect of Changing Panoply of Respiratory Support for Preterm Neonates , 2017, JAMA pediatrics.

[25]  H. Halliday,et al.  Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. , 2017, The Cochrane database of systematic reviews.

[26]  A. Ohlsson,et al.  Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. , 2016, The Cochrane database of systematic reviews.

[27]  J. Meerpohl,et al.  Inhaled Corticosteroids for Bronchopulmonary Dysplasia: A Meta-analysis , 2016, Pediatrics.

[28]  A. Kribs.  Minimally Invasive Surfactant Therapy and Noninvasive Respiratory Support. , 2016, Clinics in perinatology.

[29]  M. Kumar,et al.  Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis , 2016, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[30]  B. Darlow,et al.  Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants. , 2016, The Cochrane database of systematic reviews.

[31]  J. Beyene,et al.  Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis. , 2016, JAMA.

[32]  B. Poindexter,et al.  Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants , 2016, Pediatric Research.

[33]  G. Suresh,et al.  Should we still use vitamin A to prevent bronchopulmonary dysplasia? , 2016, Journal of Perinatology.

[34]  D. Mohamed,et al.  Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial , 2016, The Lancet.

[35]  B. Thébaud,et al.  Not another steroid trial: early low-dose hydrocortisone in preterm infants , 2016, The Lancet.

[36]  R. Green.  Early inhaled budesonide for the prevention of bronchopulmonary dysplasia , 2016 .

[37]  J. Pinheiro,et al.  Randomized trial of laryngeal mask airway versus endotracheal intubation for surfactant delivery , 2016, Journal of Perinatology.

[38]  I. Frerichs,et al.  Effect of Minimally Invasive Surfactant Therapy on Lung Volume and Ventilation in Preterm Infants. , 2016, The Journal of pediatrics.

[39]  S. Jadcherla,et al.  Systematic Review of Inhaled Bronchodilator and Corticosteroid Therapies in Infants with Bronchopulmonary Dysplasia: Implications and Future Directions , 2016, PloS one.

[40]  B. Poindexter,et al.  Comparisons and Limitations of Current Definitions of Bronchopulmonary Dysplasia for the Prematurity and Respiratory Outcomes Program. , 2015, Annals of the American Thoracic Society.

[41]  P. Mourani,et al.  Pulmonary Hypertension and Vascular Abnormalities in Bronchopulmonary Dysplasia. , 2015, Clinics in perinatology.

[42]  M. Walsh,et al.  Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. , 2015, JAMA.

[43]  K. Park,et al.  The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia , 2015, Korean journal of pediatrics.

[44]  R. Soll,et al.  Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. , 2015, The Cochrane database of systematic reviews.

[45]  W. Göpel,et al.  Nonintubated Surfactant Application vs Conventional Therapy in Extremely Preterm Infants: A Randomized Clinical Trial. , 2015, JAMA pediatrics.

[46]  D. Doherty,et al.  Nebulized pentoxifylline for reducing the duration of oxygen supplementation in extremely preterm neonates. , 2015, The Journal of pediatrics.

[47]  M. O’Reilly,et al.  Bronchopulmonary Dysplasia Early Changes Leading to Long-Term Consequences , 2015, Front. Med..

[48]  A. Ohlsson,et al.  Inositol in preterm infants at risk for or having respiratory distress syndrome. , 2015, The Cochrane database of systematic reviews.

[49]  A. Soraisham,et al.  Azithromycin and Other Macrolides for Prevention of Bronchopulmonary Dysplasia: A Systematic Review and Meta-Analysis , 2014, Neonatology.

[50]  P. Shah,et al.  Minimally invasive surfactant administration in preterm infants: a meta-narrative review. , 2014, JAMA pediatrics.

[51]  J. Carlin,et al.  The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25–28 weeks gestation , 2014, BMC Pediatrics.

[52]  Richard J Martin,et al.  Anti-Inflammatory Effect of Caffeine Is Associated with Improved Lung Function after Lipopolysaccharide-Induced Amnionitis , 2014, Neonatology.

[53]  M. Rhainds,et al.  Omega-3 Long-Chain Polyunsaturated Fatty Acids for Extremely Preterm Infants: A Systematic Review , 2014, Pediatrics.

[54]  S. Jadcherla,et al.  Inhaled Bronchodilator Use for Infants with Bronchopulmonary Dysplasia , 2014, Journal of Perinatology.

[55]  A. Herring,et al.  Diuretic Exposure in Premature Infants from 1997 to 2011 , 2014, American Journal of Perinatology.

[56]  Reint K Jellema,et al.  Effects of less-invasive surfactant administration on oxygenation, pulmonary surfactant distribution, and lung compliance in spontaneously breathing preterm lambs , 2014, Pediatric Research.

[57]  Hye Soo Yoo,et al.  Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. , 2014, The Journal of pediatrics.

[58]  M. Siew,et al.  Prophylactic erythropoietin exacerbates ventilation‐induced lung inflammation and injury in preterm lambs , 2014, The Journal of physiology.

[59]  E. Bancalari,et al.  Bronchopulmonary dysplasia: clinical perspective. , 2014, Birth defects research. Part A, Clinical and molecular teratology.

[60]  Z. Badiee,et al.  Reducing the Incidence of Chronic Lung Disease in Very Premature Infants with Aminophylline , 2014, International journal of preventive medicine.

[61]  Praveen Kumar.  Use of Inhaled Nitric Oxide in Preterm Infants , 2014, Pediatrics.

[62]  A. Cartón,et al.  Pulmonary hypertension in bronchopulmonary dysplasia: Clinical findings, cardiovascular anomalies and outcomes , 2014, Pediatric pulmonology.

[63]  J. Stocks,et al.  Early lung development: lifelong effect on respiratory health and disease. , 2013, The Lancet. Respiratory medicine.

[64]  R. Tulloh,et al.  Paediatric pulmonary hypertension and sildenafil: current practice and controversies , 2013, Archives of Disease in Childhood: Education & Practice Edition.

[65]  U. Dilmen,et al.  Surfactant Administration via Thin Catheter During Spontaneous Breathing: Randomized Controlled Trial , 2013, Pediatrics.

[66]  B. Roth,et al.  Outcome of extremely low gestational age newborns after introduction of a revised protocol to assist preterm infants in their transition to extrauterine life , 2012, Acta paediatrica.

[67]  J. Neu,et al.  Arginyl-glutamine dipeptide or docosahexaenoic acid attenuate hyperoxia-induced lung injury in neonatal mice. , 2012, Nutrition.

[68]  K. Bui,et al.  Decrease in Incidence of Bronchopulmonary Dysplasia with Erythropoietin Administration in Preterm Infants: A Retrospective Study , 2012, Neonatology.

[69]  J. Carlin,et al.  Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure , 2012, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[70]  G. Hansmann,et al.  Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension , 2012, Pulmonary circulation.

[71]  Yahya Al Ethawi.  Preliminary Evaluation of a New Technique of Minimally Invasive Surfactant Therapy , 2012, Journal of clinical neonatology.

[72]  A. Fassina,et al.  L-citrulline Prevents Alveolar and Vascular Derangement in a Rat Model of Moderate Hyperoxia-induced Lung Injury , 2012, Lung.

[73]  Shaoyi Chen,et al.  Pentoxifylline and prevention of hyperoxia-induced lung ­injury in neonatal rats , 2012, Pediatric Research.

[74]  E. Karabulut,et al.  Clarithromycin in Preventing Bronchopulmonary Dysplasia in Ureaplasma urealyticum–Positive Preterm Infants , 2011, Pediatrics.

[75]  F. Cools,et al.  Systemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial , 2011, BMC pediatrics.

[76]  W. Göpel,et al.  Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial , 2011, The Lancet.

[77]  J. Ware,et al.  Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbidities. , 2011, The Journal of pediatrics.

[78]  L. Brion,et al.  Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. , 2011, The Cochrane database of systematic reviews.

[79]  D. Osborn,et al.  Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome. , 2011, The Cochrane database of systematic reviews.

[80]  D. Rowitch,et al.  NIH Consensus Development Conference Statement: Inhaled Nitric-Oxide Therapy for Premature Infants , 2011, Pediatrics.

[81]  K. Watterberg.  Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia , 2010, Pediatrics.

[82]  A. Greenough,et al.  Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial , 2010, The Lancet.

[83]  Jennifer A. Rama,et al.  Serial Measurements of Lung Function in a Cohort of Young Children With Bronchopulmonary Dysplasia , 2010, Pediatrics.

[84]  L. Doyle,et al.  Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. , 2010, The Journal of pediatrics.

[85]  N. Ambalavanan,et al.  Pulmonary hypertension in bronchopulmonary dysplasia. , 2009, Birth defects research. Part A, Clinical and molecular teratology.

[86]  O. Liang,et al.  Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. , 2009, American journal of respiratory and critical care medicine.

[87]  M. Laughon,et al.  Prevention of bronchopulmonary dysplasia. , 2009, Seminars in fetal & neonatal medicine.

[88]  P. Tourneux,et al.  Inhaled nitric oxide improves lung structure and pulmonary hypertension in a model of bleomycin-induced bronchopulmonary dysplasia in neonatal rats. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[89]  S. Archer,et al.  Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. , 2009, American journal of respiratory and critical care medicine.

[90]  M. Summar,et al.  L-Citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[91]  C. Poets,et al.  The Neonatal European Study of Inhaled Steroids (NEUROSIS): An EU-Funded International Randomised Controlled Trial in Preterm Infants , 2009, Neonatology.

[92]  P. Calder.  Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. , 2009, Biochimie.

[93]  F. Walther,et al.  Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury , 2009, Respiratory research.

[94]  P. Mourani,et al.  Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. , 2009, The Journal of pediatrics.

[95]  T. Shaffer,et al.  Recombinant Human Clara Cell Secretory Protein Treatment Increases Lung mRNA Expression of Surfactant Proteins and Vascular Endothelial Growth Factor in a Premature Lamb Model of Respiratory Distress Syndrome , 2008, American journal of perinatology.

[96]  A. Greenough.  Clara cell secretory protein and bronchopulmonary dysplasia in prematurely born infants , 2008, European Journal of Pediatrics.

[97]  E. Eichenwald,et al.  Management and outcomes of very low birth weight. , 2008, The New England journal of medicine.

[98]  A. Gow,et al.  Plasma Biomarkers of Oxidative Stress: Relationship to Lung Disease and Inhaled Nitric Oxide Therapy in Premature Infants , 2008, Pediatrics.

[99]  A. Ventura,et al.  Chronic lung disease after premature birth. , 2008, The New England journal of medicine.

[100]  N. Hussain,et al.  Effect of a Short Course of Prednisolone in Infants With Oxygen-Dependent Bronchopulmonary Dysplasia , 2008, Pediatrics.

[101]  V. Bhandari,et al.  Hematologic Profile of Sepsis in Neonates: Neutrophil CD64 as a Diagnostic Marker , 2008, Pediatrics.

[102]  D. McElhinney,et al.  Pulmonary Artery Hypertension in Formerly Premature Infants With Bronchopulmonary Dysplasia: Clinical Features and Outcomes in the Surfactant Era , 2007, Pediatrics.

[103]  S. Abman,et al.  Early inhaled nitric oxide treatment decreases apoptosis of endothelial cells in neonatal rat lungs after vascular endothelial growth factor inhibition. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[104]  I. Rahman,et al.  Azithromycin Suppresses Activation of Nuclear Factor-kappa B and Synthesis of Pro-inflammatory Cytokines in Tracheal Aspirate Cells From Premature Infants , 2007, Pediatric Research.

[105]  F. Pillekamp,et al.  Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age ≤27 weeks) , 2007, Paediatric anaesthesia.

[106]  W. Calhoun,et al.  The role of leukotrienes in airway inflammation. , 2006, The Journal of allergy and clinical immunology.

[107]  G. Takemura,et al.  Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. , 2006, Cardiovascular research.

[108]  M. Kron,et al.  Effect of oestradiol and progesterone replacement on bronchopulmonary dysplasia in extremely preterm infants , 2006, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[109]  L. Brion,et al.  Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. , 2006, The Cochrane database of systematic reviews.

[110]  S. Abman,et al.  Nitric oxide augments fetal pulmonary artery endothelial cell angiogenesis in vitro. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[111]  L. Doyle,et al.  Caffeine therapy for apnea of prematurity. , 2006, The New England journal of medicine.

[112]  M. Ebsen,et al.  Prenatal Estrogen and Progesterone Deprivation Impairs Alveolar Formation and Fluid Clearance in Newborn Piglets , 2006, Pediatric Research.

[113]  A. Sola,et al.  Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study , 2006, Pediatrics.

[114]  R. Lauterbach,et al.  Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: A pilot clinical study , 2006, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[115]  J. Carlin,et al.  Low-Dose Dexamethasone Facilitates Extubation Among Chronically Ventilator-Dependent Infants: A Multicenter, International, Randomized, Controlled Trial , 2006, Pediatrics.

[116]  R. Schelonka,et al.  Critical Appraisal of the Role of Ureaplasma in the Development of Bronchopulmonary Dysplasia With Metaanalytic Techniques , 2005, The Pediatric infectious disease journal.

[117]  G. Korbutt,et al.  Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. , 2005, American journal of respiratory and critical care medicine.

[118]  E. Ozer,et al.  Effects of Erythropoietin on Hyperoxic Lung Injury in Neonatal Rats , 2005, Pediatric Research.

[119]  T. Shaffer,et al.  Safety, Pharmacokinetics, and Anti-inflammatory Effects of Intratracheal Recombinant Human Clara Cell Protein in Premature Infants with Respiratory Distress Syndrome , 2005, Pediatric Research.

[120]  M. Blennow,et al.  Spontaneous Breathing or Mechanical Ventilation Alters Lung Compliance and Tissue Association of Exogenous Surfactant in Preterm Newborn Rabbits , 2005, Pediatric Research.

[121]  Donald Massaro,et al.  Estrogen regulates pulmonary alveolar formation, loss, and regeneration in mice. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[122]  K. Watterberg,et al.  Prophylaxis of Early Adrenal Insufficiency to Prevent Bronchopulmonary Dysplasia: A Multicenter Trial , 2004, Pediatrics.

[123]  V. Fellman,et al.  N-Acetylcysteine Administration during the First Week of Life Does Not Improve Lung Function in Extremely Low Birth Weight Infants , 2004, Neonatology.

[124]  M. Walsh,et al.  Impact of a Physiologic Definition on Bronchopulmonary Dysplasia Rates , 2004, Pediatrics.

[125]  R. Castile,et al.  Pulmonary function in bronchopulmonary dysplasia , 2004, Pediatric pulmonology.

[126]  K. Stenmark,et al.  Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis , 2004, The Pediatric infectious disease journal.

[127]  V. Fellman,et al.  N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. , 2003, The Journal of pediatrics.

[128]  D. Phelps,et al.  Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. , 2003, The Cochrane database of systematic reviews.

[129]  J. Davis,et al.  Safety and Efficacy of Intratracheal Recombinant Human Clara Cell Protein in a Newborn Piglet Model of Acute Lung Injury , 2003, Pediatric Research.

[130]  J. Davis,et al.  Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. , 2003, Pediatrics.

[131]  W. Carlo,et al.  Long-Term Follow-up of Premature Infants Treated With Prophylactic, Intratracheal Recombinant Human CuZn Superoxide Dismutase , 2000, Journal of Perinatology.

[132]  H. So,et al.  Randomised crossover trial of salbutamol aerosol delivered by metered dose inhaler, jet nebuliser, and ultrasonic nebuliser in chronic lung disease , 1998, Archives of disease in childhood. Fetal and neonatal edition.

[133]  N. Rifai,et al.  Early High Dose Antioxidant Vitamins Do Not Prevent Bronchopulmonary Dysplasia in Premature Baboons Exposed to Prolonged Hyperosia: APilot Study , 1998, Pediatric Research.

[134]  C. Poets,et al.  Effects of salbutamol delivery from a metered dose inhaler versus jet nebulizer on dynamic lung mechanics in very preterm infants with chronic lung disease , 1997, Pediatric pulmonology.

[135]  F. Bany-Mohammed,et al.  Recombinant Human Erythropoietin: Possible Role as an Antioxidant in Premature Rabbits , 1996, Pediatric Research.

[136]  G. Coates,et al.  Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia , 1996, Pediatric pulmonology.

[137]  J. Kellner,et al.  Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a metaanalysis. , 1995, The Journal of pediatrics.

[138]  J. Zimmerman.  Bronchoalveolar inflammatory pathophysiology of bronchopulmonary dysplasia. , 1995, Clinics in perinatology.

[139]  A. Zipursky,et al.  Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1,500 g birth weight. , 1991, The European respiratory journal.

[140]  B. Schmidt,et al.  Respiratory response and pharmacokinetics of intravenous salbutamol in infants with bronchopulmonary dysplasia , 1990, Critical care medicine.

[141]  A. Froese,et al.  Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. , 1990, The American review of respiratory disease.

[142]  R. Parker,et al.  Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. , 1990, The Journal of pediatrics.

[143]  A. Leviton,et al.  Hydration during the first days of life and the risk of bronchopulmonary dysplasia in low birth weight infants. , 1990, The Journal of pediatrics.

[144]  M. Puterman,et al.  Increased compliance in response to salbutamol in premature infants with developing bronchopulmonary dysplasia. , 1989, The Journal of pediatrics.

[145]  S. DonLevy,et al.  Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic bronchopulmonary dysplasia. , 1989, The Journal of pediatrics.

[146]  A. Ohlsson,et al.  Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. , 1988, Pediatrics.

[147]  C. Lundergan,et al.  Effect of cyclooxygenase inhibition on the pulmonary vasodilator response to furosemide. , 1988, The Journal of pharmacology and experimental therapeutics.

[148]  J. Ali,et al.  Colloid osmotic pressure in pulmonary edema clearance with furosemide. , 1987, Chest.

[149]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[150]  S. Cassin,et al.  The Effects of Bumetanide and Furosemide on Lung Liquid Secretion in Fetal Sheep 1 , 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[151]  J. Brady,et al.  Controlled trial of furosemide therapy in infants with chronic lung disease. , 1985, The Journal of pediatrics.

[152]  T. Keens,et al.  Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: results of a double-blind crossover sequential trial. , 1984, Pediatrics.

[153]  A. Lazzara,et al.  Pulmonary effects of furosemide in preterm infants with lung disease. , 1983, The Journal of pediatrics.

[154]  Gerber Jg.  Role of prostaglandins in the hemodynamic and tubular effects of furosemide. , 1983 .

[155]  G. Gregory,et al.  Colloid osmotic pressure of normal newborns and premature infants , 1981, Critical care medicine.

[156]  N. Reichek,et al.  Effect of diuresis on the performance of the failing left ventricle in man. , 1981, The American journal of medicine.

[157]  R. Demling,et al.  The effect of furosemide on the pulmonary transvascular fluid filtration rate , 1978, Critical care medicine.

[158]  A. Stark,et al.  Bronchopulmonary dysplasia: possible relationship to pulmonary edema. , 1978, The Journal of pediatrics.

[159]  J. Forrester,et al.  Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. , 1973, The New England journal of medicine.

[160]  M. Ericsson,et al.  Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation , 2018, American journal of respiratory and critical care medicine.

[161]  L. Doyle,et al.  Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. , 2017, The Cochrane database of systematic reviews.

[162]  T. Yeh,et al.  Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. , 2016, American journal of respiratory and critical care medicine.

[163]  Sharon L. Wright,et al.  Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide. , 2016, The Journal of pediatrics.

[164]  W. Truog,et al.  Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits? , 2012, Journal of Perinatology.

[165]  M. Benders,et al.  Hydrocortisone vs. dexamethasone treatment for bronchopulmonary dysplasia and their effects on general movements in preterm infants , 2012, Pediatric Research.

[166]  A. V. van Kaam,et al.  Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. , 2012, The Cochrane database of systematic reviews.

[167]  S. Donn.  Preliminary evaluation of a new technique of minimally invasive surfactant therapy , 2012 .

[168]  E. Eichenwald,et al.  medical progress Management and Outcomes of Very Low Birth Weight , 2008 .

[169]  E. Cutz,et al.  Chronic Lung Disease after Premature Birth , 2008 .

[170]  L. Monte,et al.  [Bronchopulmonary dysplasia]. , 2005, Jornal de pediatria.

[171]  B. Silke.  Central hemodynamic effects of diuretic therapy in chronic heart failure , 2004, Cardiovascular Drugs and Therapy.

[172]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[173]  K. Barrington,et al.  Inhaled nitric oxide for respiratory failure in preterm infants. , 2001, The Cochrane database of systematic reviews.

[174]  S. Abbasi,et al.  Pulmonary Function and Electrolyte Balance Following Spironolactone Treatment in Preterm Infants With Chronic Lung Disease: A Double-Blind, Placebo-Controlled, Randomized Trial , 2000, Journal of Perinatology.

[175]  L. Brion,et al.  Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. , 2000, The Cochrane database of systematic reviews.

[176]  B. Freeman,et al.  Nitric oxide regulation of superoxide-dependent lung injury: oxidant-protective actions of endogenously produced and exogenously administered nitric oxide. , 1996, Free radical biology & medicine.

[177]  J. Mortola,et al.  Estrogen modulates the dimensions of the lung's gas-exchange surface area and alveoli in female rats. , 1996, The American journal of physiology.

[178]  K. Mavunda.  Effects of inhaled metaproteronol and atropine on the pulmonary mechanics of infants with bronchopulmonary dysplasia. , 1989, Pediatric pulmonology.

[179]  J. Gerber.  Role of prostaglandins in the hemodynamic and tubular effects of furosemide. , 1983, Federation proceedings.